- In June 1996, Gilead Sciences, Inc. received FDA marketing clearance for Vistide (cidofovir injection) for the treatment of CMV (cytomegalovirus) retinitis in patients with AIDS. This approval marked a significant advancement in antiviral therapy for immunocompromised individuals, providing a new treatment option to manage a potentially blinding opportunistic infection. The clearance of Vistide underscored Gilead’s commitment to developing innovative therapies for life-threatening viral infections affecting vulnerable populations.
